Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.

Thoracic cancer - 1 Oct 2021

Zhang Meng, Nie Ligong, Cheng Yuan

Abstract excerpt

The efficacy of immunotherapy in non-small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations is not well clarified, even though immunotherapy has brought revolutionary improvements in EGFR wild-type NSCLC. In addition, pseudoprogression has increased the difficulty in immunotherapy management and data on the incidence of pseudoprogression in patients with EGFR exon 20...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bevacizumab

Share to Carcinoma, Non-Small-Cell Lung

Share to Docetaxel

Share to ErbB Receptors

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 34382340
DOI: 10.1111/1759-7714.14101
PMCID: PMC8520811

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.PMID 34382340Read ↗

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectivesSemantic proximity Read ↗

EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.Semantic proximity Read ↗

First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.Semantic proximity Read ↗

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertionsSemantic proximity Read ↗

EGFR Exon 20 Insertion Mutations: CT Characteristics and Clinicopathologic Features in Non-Small Cell Lung CancerSemantic proximity Read ↗

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.Semantic proximity Read ↗

Poor efficacy of immune checkpoint inhibitors plus chemotherapy in the lung cancer patients with EGFR/ERBB2 exon 20 insertionSemantic proximity Read ↗

Small cell transformation of non-small cell lung cancer under immunotherapy: Case series and literature review.Semantic proximity Read ↗

EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.Semantic proximity Read ↗

Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R.Semantic proximity Read ↗

Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report.Semantic proximity Read ↗

Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case reportSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.